Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)

NCT06075667 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06075667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 16, 2023
Completion date
July 31, 2029
Enrollment
160 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight